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Abstract  Heart  failure  is  a  disease  with  high  direct  and  indirect  costs.  Current  treatment
includes drugs  that  alter  disease  progression  and  drugs  that  to  improve  symptoms.  Loop  diuretics
are the  cornerstone  of  congestion  relief  for  acute  management,  as  well  as  for  chronic  stabiliza-
tion. In  heart  failure  patients,  maximal  diuretic  response  is  reduced  by  many  individual  factors.
Diuretic resistance  is  deﬁned  as  failure  to  achieve  effective  congestion  relief  despite  appropri-
ate or  escalating  diuretic  doses.  Its  causes  include  impaired  delivery  of  the  diuretic  to  its  luminal
site of  action,  neurohormonal  activation,  tubular  compensatory  adaptation  and  drug  interac-
tions. Several  strategies  can  be  employed  to  aid  decongestion  of  patients  with  impaired  diuretic
response. These  include  salt  restriction,  a  higher  effective  single  dose  or  higher  dose  frequency
of loop  diuretics,  continuous  infusion  of  diuretics  and/or  sequential  nephron  blockade  through
a synergistic  combination  of  two  or  more  diuretics  from  different  classes.  Ultraﬁltration  has
also been  found  to  be  another  effective  and  safe  therapeutic  option  and  should  be  considered
in patients  with  refractory  diuretic  resistance.  Overall,  there  is  a  lack  of  high-quality  clinical
data to  guide  the  choice  of  treatment  strategy  and  therapy  should  be  tailored  on  a  case-by-case
basis.
© 2018  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
PALAVRAS-CHAVE A  resistência  aos  diuréticos  na  insuﬁciência  cardíaca  revisitada  em  2018ardíaca  é  uma  doenc¸a  com  custos  diretos  e  indiretos  elevados.  A
acos  que  alteram  a  progressão  da  doenc¸a  e  fármacos  que  melhoram
icos  de  ansa  constituem  a  pedra  basilar  no  alívio  da  congestão  quer
a  estabilizac¸ão  crónica.  Nos  doentes  com  insuﬁciência  cardíaca,  a
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diuréticos  é  deﬁnida  como  a  ausência  de  alívio  eﬁcaz  da  congestão  apesar  de  doses  apropriadas
ou crescentes  de  diuréticos.  As  causas  de  resistência  aos  diuréticos  incluem  o  compromisso  da
entrega de  diurético  no  seu  local  de  ac¸ão,  a  ativac¸ão  neuro-hormonal,  a  adaptac¸ão  compen-
satória tubular  e  interac¸ões  medicamentosas.  Podem  ser  implementadas  várias  estratégias  para
diminuir a  congestão  em  doentes  com  resposta  diurética  insuﬁciente.  Essas  estratégias  incluem
restric¸ão salina,  aumento  da  dose  ou  frequência  dos  diuréticos  de  ansa,  infusão  contínua  de
diuréticos e/ou  bloqueio  sequencial  do  nefrónio  através  da  combinac¸ão  de  dois  ou  mais  diuréti-
cos de  diferentes  classes  e  com  efeitos  sinérgicos.  A  ultraﬁltrac¸ão  tem-se  revelado  uma  outra
estratégia segura  e  eﬁcaz  e  deve  ser  considerada  em  doentes  com  resistência  aos  diuréticos
refratária.  Veriﬁca-se  globalmente  uma  escassez  de  dados  clínicos  de  elevada  qualidade  para
guiar a  escolha  da  estratégia  terapêutica  pelo  que  a  abordagem  deve  ser  adequada  caso  a  caso.
© 2018  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este e´ um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
RAPID-CHF  Relief  for  Acutely  Fluid-Overloaded
Patients  With  Decompensated  Congestive
Heart  Failure
ROSE  Renal  Optimization  Strategies  Evaluation
RAA  Renin-angiotensin-aldosterone
REWORD-HF  Reverse  Worsening  Renal  Function  in
Decompensated  Heart  Failure
UF  Ultraﬁltration
UNLOAD  Ultraﬁltration  versus  Intravenous  Diuretics
for  Patients  Hospitalized  for  Acute  Decompen-



















loop  diuretics.6--8 Loop  diuretics  are  the  cornerstone  of
congestion  relief  and  are  widely  used  for  acute  man-
agement  (up  to  90%  of  patients)  as  well  as  for  chronic
2,5,8--10Abbreviations
ATOMIC-HF  Acute  Treatment  with  Omecamtiv  Mecar-
bil  to  Increase  Contractility  in  Acute  Heart
Failure
BNP  B-type  natriuretic  peptide
BLAST-AHF  Biased  ligand  of  the  angiotensin  II  type  1
receptor  in  patients  with  acute  heart  failure
CARRESS-HF  Cardiorenal  Rescue  Study  in  Acute
Decompensated  Heart  Failure
CKD  Chronic  kidney  disease
CUORE  Continuous  Ultraﬁltration  for  Congestive
Heart  Failure
DOSE  Diuretic  Optimization  Strategies  Evaluation
DAD-HF  II  Dopamine  in  Acute  Decompensated  Heart
Failure  II
RELAX-AHF-2  Efﬁcacy,  Safety  and  Tolerability  of  Sere-
laxin  When  Added  to  Standard  Therapy  in
Acute  Heart  Failure
RELAX-AHF  Efﬁcacy  and  Safety  of  Relaxin  for  the
Treatment  of  Acute  Heart  Failure
TRUE-AHF  Efﬁcacy  and  Safety  of  Ularitide  for  the
Treatment  of  Acute  Decompensated  Heart
Failure
EVEREST  Efﬁcacy  of  Vasopressin  Antagonism  in  Heart
Failure  Outcome  Study  with  Tolvaptan
EPICA  Epidemiologia  da  Insuﬁciência  Cardiaca  e
Aprendizagem
HF  Heart  failure
NT-proBNP  N-terminal  pro--BNP
NSAID  Nonsteroidal  anti-inﬂammatory  drug
PROTECT  Placebo-Controlled  Randomized  Study  of
the  Selective  Adenosine  A1  Receptor  Antago-
nist  Rolofylline  for  Patients  Hospitalized  with
Acute  Decompensated  Heart  Failure  and  Vol-
ume  Overload  to  Assess  Treatment  Effect  on
Congestion  and  Renal  Function
REVIVE  Randomized  Multicenter  Evaluation  of  Intra-
venous  Levosimendan  Efﬁcacy sULTRADISCO  Ultraﬁltration  vs.  Diuretics  in  Decompen-
sated  Heart  Failure
ntroduction
he  incidence  of  heart  failure  (HF)  is  1%  among  American
atients  over  65  years  of  age.1,2 Portuguese  ﬁgures  from  the
002  Epidemiologia  da  Insuﬁciência  Cardiaca  e  Aprendiza-
em  (EPICA)  study  concluded  that  the  overall  prevalence
f  HF  is  4.4%,  peaking  at  16%  in  those  over  80  years  of
ge.3 It  continues  to  be  the  primary  discharge  diagnosis
mong  elderly  American  patients.4 Hospitalization  for  HF
onstitutes  an  ominous  sign,  with  half  of  patients  read-
itted  in  the  subsequent  six  months  and  a  mortality  rate
f  25-35%  at  the  end  of  the  ﬁrst  year.4,5 Consequently,  HF
s  a  high  burden  disease  with  elevated  direct  and  indirect
osts.1
Current  treatment  includes  drugs  that  alter  disease  pro-
ression  such  as  angiotensin  converting  enzyme  inhibitors,
ngiotensin  II  receptor  blockers  or,  more  recently,  sacubi-
ril/valsartan,  beta-blockers  and  mineralocorticoid  receptor
ntagonists  --  in  HF  with  reduced  ejection  fraction  --  and
rugs  used  to  improve  symptoms  such  as  diuretics,  namelytabilization.

























cFigure  1  Pathophysiology-bas
Despite  the  fact  that  diuretics  themselves  are  not  linked
to  increased  survival,6,8 diuretic  efﬁcacy  has  been  shown  to
prolong  event-free  survival,  regardless  of  glomerular  ﬁltra-
tion  rate.5,11--13
In  this  review,  we  discuss  the  underlying  pathophysio-
logy  of  diuretic  resistance  in  HF  patients,  while  providing
several  currently  available  evidence-based  pharmacological
and  non-pharmacological  strategies  to  overcome  this  prob-
lem  (Figure  1).  The  aim  of  this  article  is  to  summarize  the
existing  data  and  highlight  recent  research  on  the  subject,
providing  an  up-to-date  and  practical  approach  to  diuretic
resistance.
Diuretic resistance -- deﬁning the problem
There  is  ample  variation  in  the  deﬁnition  of  diuretic-
resistant  patients.13 The  general  deﬁnition  refers  to  the
failure  to  achieve  effective  congestion  relief  despite  appro-
priate  or  escalating  doses  of  diuretics.14,15
Some  early  reports  estimated  the  prevalence  of  diuretic
resistance  to  be  20-30%  among  HF  patients.16,17 However,  the
lack  of  a  formal  deﬁnition  makes  it  impossible  to  properly
assess  the  numbers.9,13,15
Recent  data  link  furosemide-equivalent  doses  of  loop
diuretics  (for  intravenous  diuretics,  1  mg  of  bumetanide,
20  mg  of  torsemide  and  40  mg  of  furosemide11)  to  changes
in  several  parameters  such  as  weight  loss,  urine  output  or
natriuresis  as  means  to  diagnose  diuretic  resistance.13 These
studies  are  summarized  in  Table  1.
Depending  on  the  study,  poor  diuretic  response  may  be
deﬁned  as:  a  weight  change  of  0  to  2.7  kg  per  40  mg  of




upproach  to  diuretic  resistance.
1400  ml  per  40  mg  of  furosemide  (or  equivalent)18;
 fractional  excretion  of  sodium  at  baseline  <0.2%19;
 urinary  sodium  concentration  and  urinary  furosemide
oncentration  ratio  (both  obtained  from  spot  urine  samples)
2  mmol/mg12; and/or  lower  chloride  levels  at  baseline  (97
o  103  mEq/l).20 However,  the  correlation  between  differ-
nt  metrics  remains  poor  and  there  is  no  cut-off  to  establish
ctual  diuretic  resistance.13 Prospective  trials  are  needed  to
roperly  validate  these  metrics.21
Predictors  of  diuretic  resistance,  on  the  other  hand,  are
ore  ﬁrmly  established  between  studies  and  include:  low
ystemic  blood  pressure,  elevated  blood  urea  nitrogen,  HF
f  ischemic  origin  and  diabetes.5,11,18,22 These  studies  also
ound  that  diuretic  resistance  is  an  independent  predictor
f  worse  in-hospital  outcomes  for  HF,  early  post-discharge
ortality  and  increased  HF  rehospitalization.
harmacokinetics & pharmacodynamics
f  loop diuretics
he  relationship  between  loop  diuretic  concentration  and
atriuresis  can  be  illustrated  through  an  S-shaped  dose-
esponse  curve,14 which  means  that  a  minimal  concentration
ust  be  reached  at  the  site  of  action  before  any  response
s  noted.8 A  normal  dose-response  relationship  can  be  dis-
orted  by  a  variety  of  clinical  conditions.  In  HF  patients,  the
urve  is  shifted  downwards  and  to  the  right,  which  translates
nto  a  decreased  maximal  diuretic  response.8 Furthermore,
uring  hospitalization,  diuretic  response  is  affected  by  many
ndividual  factors14 including,  but  not  limited  to,  renal  fail-
re,  which  also  shifts  the  curve  to  the  right,  meaning  a
938  S.I.  Jardim  et  al.
Table  1  Relationship  between  diuretic  efﬁcacy  and  clinical  outcomes  in  heart  failure.
Author  (year)  Metric  Findings  in  patients  with  low  diuretic  efﬁcacy
Testani  et  al.  (2014)11 Net  ﬂuid  loss Higher  all-cause  mortality  after  5  years  (Penn
Cohort)/180  days  (Evaluation  Study  of  Congestive  Heart
Failure  and  Pulmonary  Artery  Catheterization
Effectiveness  Cohort)
Valente et  al.  (2014)5 Weight  loss  Higher  heart  failure  readmissions  after  60  days
Higher  death,  heart  failure  or  renal-related
readmissions  after  60  days
Higher  all-cause  mortality  after  180  days
Voors et  al.  (2014)22 Weight  loss Higher  death,  heart  failure  or  renal-related
readmissions  after  60  days
Neutral  effect  on  all-cause  mortality  after  180  days
Singh et  al.  (2014)12 Urinary  sodium
Furosemide  concentration
Higher  death,  transplantation  or  heart  failure
readmission  after  5  months
ter Maaten  et  al.  (2015)18 Weight  loss
Urine  output
Higher  death  or  heart  failure  readmission  after  30  days
Verbrugge et  al.  (2015)10 Natriuresis  Higher  death  or  heart  failure  readmission  after  188  days
Kumar et  al.  (2015)19 Fractional  sodium  excretion  Higher  all-cause  mortality  after  30  days
Ter Maaten  et  al.  (2016)20 Chloride  levels  Higher  mortality  through  180  days




























































Adapted from Verbrugge FH, Mullens W & Tang WH (2016).13
igher  dose  of  diuretics  is  needed  to  achieve  the  same
egree  of  natriuresis.8
athophysiology of diuretic resistance
he  pathophysiology  of  diuretic  resistance  is  complex  and
everal  causes  may  be  involved  (Table  2).15 It  stems  from
ultiple  factors,  including  reduced  delivery  of  the  diuretic
o  its  luminal  site  of  action,  neurohormonal  activation,  tubu-
ar  compensatory  adaptation  and  drug  interactions.15
educed  delivery  of  the  diuretic  to  its  site  of  action
educed  delivery  of  the  diuretic  to  its  site  of  action  is  closely
elated  to  its  decreased  bioavailability.
In  HF  patients,  increased  peripheral  and  bowel  wall
dema  leads  to  reduced  absorption  of  the  diuretic,  with  a
ore  marked  effect  when  oral  furosemide  is  used.21
HF  itself  as  well  as  concurrent  chronic  kidney  disease
CKD)  (urate  and  other  competing  organic  acids)  may  lead
o  decreased  glomerular  ﬁltration  rate,  which  in  turns
eads  to  impaired  secretion  of  diuretics  (namely  furosemide)
y  the  organic  acid  transporter  into  the  proximal  tubule.
educed  glomerular  ﬁltration  rate  can,  therefore,  reduce
elivery  or  reduce  active  secretion  of  loop  diuretics  into
heir  site  of  action.23 Moreover,  CKD  has  been  proposed
s  a  contributing  factor  to  the  development  of  HF  overall,
egardless  of  left  ventricular  ejection  fraction.  CKD  leads  to
olume  retention,  altered  calcium--phosphate  metabolism,
yperparathyroidism,  vitamin  D  deﬁciency,  anemia,  and  the
ccumulation  of  uremic  toxins.24 Renal  dysfunction  caused
y  intra-abdominal  hypertension  and  cardiorenal  syndrome
re  also  plausible  mechanisms  of  diuretic  resistance  through
enous  congestion.9,25 Intra-abdominal  hypertension  relief
mproves  renal  perfusion,  renal  ﬁltration  and  diuresis.  It
t
H
as  usually  present  in  up  to  60%  of  acutely  decompensated
F  patients.25 It  is  very  important  to  emphasize  the  need
o  detect  third-space  overload  as  opposed  to  intravascu-
ar  overload  because  both  the  kidneys  and  diuretic  therapy
an  only  act  in  vascular  overload.  Persistent  diuretic  use
n  patients  who  are  already  suffering  from  intravascular
olume  depletion  further  activates  the  renin-angiotensin-
ldosterone  (RAA)  axis  and  makes  diuretic  resistance
ependent  on  renal  blood  ﬂow.  Urinary  sodium  and  chlo-
ide  measurements  may  indicate  when  vascular  volume
as  been  optimized  because  they  decrease  as  euvolemia
pproaches.13 These  may  serve  as  more  reliable  markers
f  decongestion  as  opposed  to  the  clinical  signs  and  symp-
oms  traditionally  used  to  guide  decongestive  therapy.26
linical  signs  and  symptoms  lack  sensitivity  and  speciﬁcity
ut  do  raise  the  need  for  further  clinical  evaluation.  Natri-
retic  peptides  are  helpful  for  diagnosis  and  prognosis  but
ack  the  power  to  properly  monitor  volume  status.26 Newer
pproaches  point  to  quantitative  blood  volume  analysis  as
eans  to  differentiate  hypervolemia  proﬁles.  Appropriate
roﬁling  of  volume  overload  in  HF,  according  to  blood  vol-
me,  has  therapeutic  implications  and  may  aid  patients
ith  diuretic  resistance,  redirecting  them  to  other  forms
f  decongestion.26
Another  mechanism  of  diuretic  activity  impairment
nvolves  increased  re-absorption  of  sodium  and  chloride  in
he  proximal  tubule,  leading  to  decreased  delivery  of  these
ubstrates  to  the  distal  areas  of  the  nephron  where  loop
iuretics  act.  This  mechanism  causes  diuretic  resistance
hrough  decreased  substrate  availability  to  the  sodium-
otassium-chloride  cotransport  system.13
Albumin  levels  also  correlate  to  diuretic  action  because
hey  are  high  afﬁnity  albumin-binding  molecules  (>90%).9
ypoalbuminemia  increases  the  drug  distribution  volume
nd  prevents  suitable  kidney  delivery.  On  the  other  hand,
A  2018  overview  of  diuretic  resistance  in  heart  failure  




Third  space  overload  with  intravascular  volume  depletion
Nonadherence  to  recommended  sodium  and/or  ﬂuid
restriction
Poor diuretic  delivery  to  the  nephron  lumen
Nonadherence
Dose  too  low  or  too  infrequent
Poor  absorption  (example:  edematous  gut)
Hypoalbuminemia  and  nephrotic  syndrome
Hepatic  cirrhosis
Reduced  diuretic  secretion
Tubular  uptake  of  diuretic  impaired  by  uremic  toxins
Decreased  kidney  blood  ﬂow
Decreased  functional  kidney  mass
Insufﬁcient  kidney  response  to  drug
Low  glomerular  ﬁltration  rate
Decreased  effective  intravascular  volume  despite  elevated
total extracellular  ﬂuid  volume
Activation  of  the  renin-angiotensin-aldosterone  axis  and
renal  sympathetic  nerves
Increased  sodium  delivery  and  absorption  in  distal  tubular
segments
Compensatory  retention  of  sodium  after  the  effective
period  of  the  diuretic




















































nUse  of  nonsteroidal  anti-inﬂammatory  drugs
Adapted from Hoorn EJ & Ellison DH (2017).36
high  levels  of  albuminuria  decrease  loop  diuretic  deliv-
ery.  Increased  urine  albumin  binds  to  diuretics,  preventing
their  ligation  to  the  sodium-potassium-chloride  receptors
and  thus  impairing  their  action.9
Neurohormonal  activation
Neurohormonal  activation  is  strongly  related  to  RAA  axis
upregulation.  Loop  diuretics  can  activate  the  RAA  axis
through  a  variety  of  mechanisms.15 They  induce  renin  secre-
tion  through  the  direct  blockade  of  the  macula  densa
sodium-potassium-chloride  cotransport  system,  thus  leading
to  increased  renin  and  aldosterone  in  a  volume-independent
pathway.8 Furthermore,  diuretics  induce  renal  prostacy-
clin  production,  which  increases  renin  secretion.  Finally,
diuretics  induce  volume  contraction,  thus  activating  renin
secretion  through  vascular  stimulation.8 RAA  axis  activation
eventually  leads  to  increased  sodium  reabsorption,  prom-
pting  the  onset  of  post-diuretic  sodium  retention  and  the
braking  phenomenon.15 Post-diuretic  sodium  retention  is
one  of  the  processes  through  which  diuretic  resistance  may
be  established  and  it  arises  as  soon  as  the  concentration
of  diuretic  in  the  tubular  ﬂuid  drops  below  the  therapeutic
threshold.15 A  negative  net  sodium  balance  in  the  24  hours
between  natriuresis  and  post-diuretic  sodium  retention  may




endering  the  diuretic  effect  insigniﬁcant.15 The  braking
henomenon,  on  the  other  hand,  is  deﬁned  as  the  decrease
n  diuresis  volume  after  multiple  same-dose  administrations
f  diuretic.  This  is  linked  to  RAA  axis  activation  and  com-
ensatory  changes  in  the  nephron.9
ubular  compensatory  readaptation
ubular  readaptation  is  another  mechanism  that  helps
xplain  reduced  diuretic  response.21 Owing  to  the  above-
entioned  activation  of  the  RAA  axis,  as  well  as  the  braking
henomenon,  proximal  tubular  reabsorption  arises,  leading
o  increased  sodium  uptake  in  this  area  of  the  nephron.21
imultaneously,  the  chronic  use  of  loop  diuretics  -- which
nhibit  sodium  uptake  in  the  loop  of  Henle  --  leads  to
ncreased  sodium  delivery  to  the  distal  tubular  system,
esulting  in  compensatory  hyperplasia  and  hypertrophy.9
his  means  that  the  patient  would  retain  more  sodium  and
hus  water  than  a  diuretic-naïve  patient.13,21 This  resistance
echanism  can  be  overcome  using  a  sequential  nephron
lockade  with  thiazide  diuretics.9
rug  interactions
ome  drugs,  such  as  nonsteroidal  anti-inﬂammatory  drugs
NSAIDs),  can  reduce  the  effect  of  diuretics.21
NSAIDs  may  cause  diuretic  resistance  in  a  number
f  ways,  particularly:  decreased  prostaglandin  synthesis,
ecreased  renal  vasodilation,  increased  renal  reabsorption
n  areas  of  the  nephron  other  than  the  loop  of  Henle  and
ypertension.9 Evidence  regarding  the  effect  of  low-dose
spirin  (<1  mg/kg/day)  on  diuretic  response  in  particu-
ar  is  more  scarce  and  controversial.  A  previous  study
eported  that  chronic  low-dose  aspirin  could  profoundly
ffect  platelet  prostaglandin  production  without  affect-
ng  diuretic-stimulated  renal  prostacyclin  production  or
lasma  renin  activity.27 However,  more  recently,  Jhund  et  al.
emonstrated  that  the  venodilation  that  occurs  follow-
ng  furosemide  administration  could  be  inhibited  by  both
igh  and  low  dose-aspirin.28 Furthermore,  Hall  noted  an
mportant  reduction  in  the  need  for  diuretics  when  daily
spirin  administration  was  stopped.29 There  is  also  some
vidence  that  aspirin,  even  at  a  low  dose,  may  neutral-
ze  the  favorable  effects  of  angiotensin-converting  enzyme
nhibitors  by  blocking  prostaglandin  production  and  enhanc-
ng  the  vasoconstrictor  potential  of  endothelin.30 In  patients
ith  HF,  aspirin  should  be  avoided  wherever  possible  and
ther  antithrombotic  agents  that  respect  the  integrity  of
rostaglandin  metabolism  should  be  considered.
reatment options for  diuretic resistance
verall,  there  is  a  lack  of  high-quality  clinical  data  to
uide  the  choice  of  treatment  strategy  to  overcome  diuretic
esistance.31 Several  strategies  can  be  employed  to  aid
econgestion  in  patients  with  acute  HF  manifesting  an
mpaired  diuretic  response.  These  include  diuretic  and
ondiuretic  strategies  (Table  3).21Before  considering  the  following  treatment  options,
ther  causes  of  apparent  diuretic  resistance,  such  as  third-
pace  overload  with  intravascular  volume  depletion,  must
e  ruled  out.
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Table  3  Strategies  for  treating  diuretic  resistance.
Strategy  Summary  of  evidence  Recommendation
Initial  measures
Intravenous  diuretics  Improved  pharmacokinetics  in  compensated
heart  failure
Initial  measure  in  hospitalized
patients
Increase diuretic  dose  Doses  of  ≥500  mg/day  of  oral  furosemide
were  safe
High  intravenous  doses  were  safe  and  were
more  effective
Consider  in  mildly  symptomatic
ambulatory  patients
Use alternative  loop  diuretic
(bumetanide  and  torsemide)
Greater  enteral  absorption  and  less
affected  by  edematous  states
Consider  in  case  of  poor  response  to
oral  furosemide
Continuous  infusion Lower  total  daily  doses  to  elicit  the  same
degree  of  natriuresis  compared  to  bolus
doses  without  better  symptom  relief  or
creatinine  improvements
Consider  in  case  of  inadequate
response  to  bolus  doses
Combination  of  intravenous  loop
diuretics  with  one  or  more  diuretics
from  different  classes
-  Thiazide/Metolazone  --  Increased  urine
sodium  and/or  weight  loss
- Acetazolamide  --  increased  diuresis
Consider  in  case  of  inadequate
response  to  increasing  doses  of  IV
loop  diuretics
- Mineralocorticoid  receptor  antagonist  --
increased  diuresis  and  faster  symptom  relief
Consider  in  ambulatory  or
outpatients  with  an  inadequate
response  to  loop  diuretics
Advanced measures
Hypertonic  saline  infusion  Improved  diuresis  and  renal  function,  and
shortened  hospitalizations
Consider  when  the  above  options
have  failed
Dopamine  Similar  urine  output  when  added  to
low-dose  intravenous  furosemide  compared
with high-dose  intravenous  furosemide
alone
Subsequent  trials  have  failed  to
demonstrate  a  beneﬁt
Consider  only  when  all  other  options
have  failed
Nesiritide  No  improvement  in  urine  output,  hospital
ality


































rreadmission  or  mort
Adapted from Bowman, Nawarskas & Anderson (2016).31
alt  restriction
ietary  sodium  restriction  is  a  key  determinant  of  diuretic
fﬁcacy.  When  dietary  sodium  intake  is  high,  post-diuretic
odium  retention  compensates  almost  entirely  for  the  loop-
iuretic-induced  sodium  loss.  Conversely,  if  sodium  intake
s  restricted,  post-diuretic  sodium  retention  is  minimized,
esulting  in  a  negative  ﬂuid  and  sodium  balance.32 Thus,
estricting  sodium  intake  to  less  than  100  mEq/day  mit-
gates  the  effect  of  post-diuretic  sodium  retention  and
elps  achieve  a  negative  sodium  balance.  A  24-hour  uri-
ary  sodium  excretion  of  more  than  100  mEq/day  or  a
ractional  excretion  of  sodium  value  >2%  indicates  non-
ompliance  with  sodium  restriction  and  rules  out  true
iuretic  resistance.15
iscontinue  concomitant  use  of  nonsteroidal
nti-inﬂammatory  drugsoncomitant  use  of  NSAIDs  is  a  major  cause  of  diuretic





stablish  the  effective  single  dose
iuretics  have  a  dose-response  curve  and  the  effect  only
egins  once  the  diuretic  level  reaches  a  therapeutic  thresh-
ld  within  the  renal  tubular  lumen.  In  conditions  such  as  CKD
nd  cardiorenal  syndrome,  the  dose-response  curve  shifts
ownwards  and  towards  the  right.  This  means  that  these
atients  need  higher  doses  of  loop  diuretics  to  achieve  the
herapeutic  drug  level  at  the  site  of  action.  Diuretic  doses
elow  said  threshold  are  ineffective,  so  a  higher  effective
ingle  loop  diuretic  dose  is  needed  rather  than  administering
n  inadequate  dose  more  frequently.15
ncrease  dose  frequency  of  loop  diuretics
ecause  most  loop  diuretics  are  short  acting,  increasing
he  dose  frequency  can  help  overcome  post-diuretic  sodium
etention  and  restore  diuretic  response.15iuretic  substitution
astrointestinal  absorption  and  the  bioavailability  of  dif-
erent  diuretics  belonging  to  the  same  class  can  vary
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Table  4  Dosage  regimens  for  continuous  intravenous  diuretic  administration.
Creatinine  clearance  (ml/min)  Loading  dose  (mg)  Infusion  rate  (mg/h)
All  levels  <25  25-75  >75
Furosemide  40  20  then  40  10  then  20  10
Bumetanide  1  1  then  2  0.5  then  1  0.5
Torsemide 20  10  then  20  5  then  10  5
can  be  an  effective  approach  in  resistant  cases  (Table  5).15
For  edematous  disorders  other  than  liver  cirrhosis  and
ascites,  the  evidence  for  speciﬁc  diuretic  combinations  is
less  clear.36 The  use  of  a  loop  diuretic  and  a  thiazide  or
thiazide-like  diuretic  with  or  without  a  potassium-sparing
agent  is  most  common  in  practice.15 Nevertheless,  in  the
absence  of  evidence  on  the  comparative  efﬁcacies  of  the
various  diuretic  combinations,  choosing  a  strategy  should  be
based  on  patient-speciﬁc  factors  and  the  side  effect  proﬁles
of  the  different  combinations.31
Thiazide  diuretics  inhibit  sodium  reabsorption  in  the
distal  convoluted  tubule  and  can  thus  counteract  com-
pensatory  distal  tubular  hypertrophy.31 Metolazone  and
hydrochlorothiazide  are  the  two  thiazides  most  commonly
used  in  combination  with  furosemide,  although  there  is
no  clear  evidence  that  one  is  superior  to  the  other,  nei-
ther  in  terms  of  their  efﬁcacy  in  increasing  diuresis  nor
their  safety  with  regard  to  renal  function  and  electrolyte
abnormalities.32,37,38 When  initiating  combination  therapy,
thiazides  should  be  administered  before  intravenous  loop
diuretics  to  allow  enough  time  for  the  full  blockade  of  the
distal  nephron.32 Case  studies  and  small  observational  tri-
als  reported  effective  diuresis  in  75-90%  of  patients  who
received  thiazide  diuretics  in  addition  to  loop  diuretic
therapy.31 However,  one  drawback  of  thiazide-type  diuretics
is  that  they  limit  the  kidneys’  capacity  to  produce  diluted
urine  and  thus  free  water  clearance  and  they  should  there-
fore  be  avoided  in  hypotonic  hyponatremia.13
There  is  a  paucity  of  data  regarding  speciﬁc  mineralo-
corticoid  receptor  antagonists  use  in  acute  HF  and  the
combination  of  spironolactone  and  loop  diuretics  has  not
been  shown  to  be  synergistic.  Nevertheless,  said  drugs
Table  5  Combination  diuretic  therapy.
To  an  effective  or  maximal  safe  dose  of  a  loop  diuretic  add:
Distal  convoluted  tubule  diuretics
Metolazone  2.5-10  mg  per  os  daily  (duration  or  frequency
adjusted  based  on  the  target  weight)
Hydrochlorothiazide  (or  equivalent)  25-100  mg  per  os  daily
Chlorothiazide  500-1000  mg  intravenously
Proximal  tubule  diuretics
Acetazolamide  250-375  mg  daily  or  up  to  500  mg
intravenously
Potassium-sparing  diureticsAdapted from Brater (2011).35
considerably  and  this  could  be  a  factor  behind  a  poor
response.  Furosemide  has  a  bioavailability  of  about  50%,
whereas  torsemide  and  bumetanide  have  almost  complete
absorption  (80-100%).  At  times,  replacing  furosemide  with
comparable  doses  of  bumetanide  or  torsemide  can  be
enough  to  improve  diuresis.15
Intravenous  diuretics
Sometimes,  administering  diuretics  intravenously  instead
of  orally  is  all  that  is  needed  to  improve  diuresis.  Oral
absorption  may  be  altered  in  the  presence  of  gastroin-
testinal  edema,  gastroparesis  and  delayed  gastric  emptying.
Drug  concentration  at  the  site  of  diuretic  action  in  the
tubule  lumen  may  be  inadequate,  due  to  decompensated
HF,  renal  hypoperfusion  or  impaired  secretion  as  a  result  of
hypoalbuminemia.32
Compared  to  bolus  doses,  continuous  diuretic  infusion
may  be  more  effective  in  improving  diuresis.  It  may  decrease
ﬂuctuations  in  intravascular  volume,  resulting  in  a  more
gradual  and  relatively  constant  hourly  urine  output  and
limiting  the  effect  of  post-diuretic  sodium  retention.  Some
studies  found  that  furosemide  administered  as  a  contin-
uous  infusion  was  more  effective  than  intermittent  bolus
doses,  since  signiﬁcantly  less  furosemide  was  required  to
produce  the  same  diuresis  and  due  to  the  elimination  of  a
diuretic-free  interval  (during  which  compensatory  sodium
retention  occurs).  Said  studies  found  no  signiﬁcant  differ-
ences  in  adverse  effects  and  no  change  in  serum  creatinine
or  hospital  mortality.33,34 Other  studies  reported  that  both
regimens  were  equally  effective  in  achieving  a  negative  ﬂuid
balance.32 In  the  Diuretic  Optimization  Strategies  Evalua-
tion  (DOSE)  trial,  there  were  no  signiﬁcant  differences  in
patients’  global  symptom  assessment  or  in  the  change  in
renal  function  between  the  two  strategies.2 Despite  the
conﬂicting  evidence,  pharmacodynamic  concepts  support
the  improved  efﬁcacy  of  continuous  infusion  of  all  loop
diuretics  except  ethacrynic  acid.  A  bolus  dose  of  a  loop
diuretic  should  be  administered  before  initiating  a  con-
tinuous  infusion  or  when  the  infusion  rate  is  increased  in
order  to  decrease  the  time  for  the  drug’s  onset  of  action
(Table  4).32,35
Sequential  nephron  blockadeA  sequential  sodium  uptake  blockade  in  different  nephron
segments  by  means  of  a  combination  of  two  or  more
diuretics  from  different  classes  may  produce  an  additive  or
synergistic  mechanism  of  action  and  diuretic  response,  and
Spironolactone  100-200  mg  daily
Amiloride  5-10  mg  daily









































































































xhibit  mild  but  effective  natriuretic  effects  and  minimize
otassium  wasting  by  loop  diuretics.8,13 Moreover,  spirono-
actone  or  eplerenone  are  recommended  in  all  symptomatic
atients  (despite  treatment  with  an  angiotensin-converting
nzyme  inhibitor  and  a  beta-blocker)  with  HF  and  a  reduced
jection  fraction  in  order  to  reduce  mortality  and  HF
ospitalization.31 Therefore,  there  may  be  a  strong  rationale
o  continue  and  even  increase  dosing  of  these  drugs  when
he  glomerular  ﬁltration  rate  is  stable  and  serum  potassium
evels  are  less  than  5.5  mEq/l.8,13
While  the  diuretic  and  natriuretic  capacity  of  acetazo-
amide  is  poor  on  its  own,  it  could  well  be  a  very  efﬁcient
ooster  of  diuretic  efﬁcacy.  The  combination  of  acetazo-
amide  and  a  loop  diuretic  can  be  very  effective,  blocking
ore  than  90%  of  sodium  reabsorption  in  the  nephron.
oreover,  it  reduces  renin  release  with  potentially  favor-
ble  effects  on  neurohormonal  activation.  However,  there
re  currently  no  data  on  the  beneﬁts  of  acetazolamide
s  add-on  therapy  and  long-term  use  can  cause  metabolic
cidosis.13,15
Combination  therapy  is  associated  with  a  signiﬁcant
ncrease  in  adverse  effects  such  as  electrolyte  imbalances,
ehydration  and  renal  impairment.  It  requires  careful  mon-
toring  and  is  best  reserved  for  the  occasional  patient  with
igh  resistance  to  loop  diuretics.15,32
anagement  of  intra-abdominal  pressure
ntra-abdominal  hypertension  is  deﬁned  as  a  sustained  intra-
bdominal  pressure  of  12  mmHg  or  above.  Splanchnic  and
nterstitial  congestion  may  cause  elevated  intra-abdominal
ressure  in  the  absence  of  ascites  in  acute  decompensated
F.  In  such  patients,  a  rise  in  intra-abdominal  pressure
ncreases  renal  venous  pressure,  thereby  reducing  the  tran-
renal  perfusion  gradient  and  renal  perfusion.  Elevated
ntra-abdominal  pressure  also  causes  increased  renal  inter-
titial  pressure  that  opposes  net  ﬁltration  pressure.  Both
ontribute  to  renal  impairment  and  diuretic  resistance.
hen  intravenous  loop  diuretic  therapy  fails,  measuring
ntra-abdominal  pressure  is  an  inexpensive  and  minimally
nvasive  procedure  that  rules  out  a  diuretic  resistance  cause.
f  intra-abdominal  hypertension  or  abdominal  compartment
yndrome  (deﬁned  as  a  sustained  intra-abdominal  pressure
f  >20  mmHg  which  is  associated  with  new  organ  dysfunc-
ion)  is  identiﬁed,  a  reduction  in  intra-abdominal  pressure
y  mobilizing  third-space  ﬂuid  can  be  achieved  through
 combination  of  diuretics,  vasodilators  and/or  inotropes.
bundant  ascites  can  be  managed  with  paracentesis,  ultra-
ound  or  computer  tomography  guidance  if  needed.  In
ertain  patients,  ultraﬁltration  (UF)  may  be  appropriate.
he  therapeutic  aim  is  to  achieve  an  abdominal  perfusion
ressure  (calculated  as  the  mean  arterial  pressure  minus
he  intra-abdominal  pressure)  of  over  60  mmHg  (with  an
ntra-abdominal  pressure  of  5  to  7  mmHg),  which  signiﬁes
 favorable  outcome  (improvement  in  renal  perfusion,  renal
ltration  and  diuresis).25nfusion  with  albumin
imultaneous  infusion  of  a  diuretic  and  albumin  could
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andomized  clinical  trials  of  adults  with  hypoalbuminemia,
omparing  the  co-administration  of  loop  diuretics  and  albu-
in  versus  loop  diuretics  alone,  found  transient  effects  of
odest  clinical  signiﬁcance  with  the  former  strategy.39 How-
ver,  this  intervention  should  only  be  considered  in  severely
ypoalbuminemic  patients  when  the  approaches  discussed
bove  have  failed.15
enal-dose  dopamine
ow  doses  of  dopamine  (<3  g/kg/min)  selectively  work  on
eripheral  dopaminergic  receptors  resulting  in  vasodilation
n  the  renal,  coronary,  splanchnic  and  cerebral  circulations.
wo  recent  trials  of  dopamine  in  acute  HF  --  the  Dopamine  in
cute  Decompensated  Heart  Failure  II  (DAD-HF  II)  trial  and
he  Renal  Optimization  Strategies  Evaluation  (ROSE)  trial  --
ave  shown  no  added  beneﬁt  with  the  addition  of  dopamine
o  standard  therapy  with  high-dose  diuretics.  Thus,  on  the
asis  of  current  data,  dopamine  has  no  role  in  nonhypoten-
ive  patients  with  acute  HF.  In  the  absence  of  cardiogenic
hock,  however,  the  role  of  low-dose  dopamine  in  acute  HF
ith  hypotension  merits  further  study.21,31
lternative  pharmacological  therapies
ypertonic  saline  works  osmotically  to  pull  free  water  from
he  interstitial  ﬂuid  into  the  renal  vasculature.  In  addition
o  increasing  renal  blood  ﬂow,  it  improves  sodium  delivery
o  the  loop  of  Henle,  thus  restoring  some  of  the  loop  diuret-
cs’  effect.  Several  studies  have  reported  better  diuresis,
mproved  renal  function  and  shorter  hospital  stays  when
ypertonic  saline  is  added  to  loop  diuretic  therapy.31
Nesiritide  is  a  synthetic  B-type  natriuretic  peptide  (BNP)
pproved  by  the  Food  and  Drug  Administration  for  symp-
omatic  relief  due  to  its  favorable  effects  on  hemodynamics,
yspnea  and  renal  function.  However,  both  the  ROSE  trial
nd  ter  Maaten  et  al.  (2015)  found  no  additive  effect  of
sing  low-dose  nesiritide  added  to  diuretic  therapy  in  terms
f  decongestion  or  improved  renal  function.  Experimental
esearch  has  shown  that  renal  delivery  of  BNP  had  signiﬁ-
antly  greater  beneﬁcial  effects  than  systemic  delivery.  It
ould  be  that  a  higher  systemic  dose  is  needed;  however,
he  usage  thereof  would  increase  the  incidence  of  adverse
ffects  such  as  hypotension.18,40
Furthermore,  it  is  worth  noting  that  HF  trials  on  nesiritide
nd  dopamine  have  not  been  speciﬁc  to  patients  exhibiting
 resistance  to  loop  diuretics.31
Vasopressin-2-receptor  antagonists  may  promote  aquare-
is  by  blocking  the  effects  of  vasopressin  on  the  vasopressin
 receptors  located  in  the  collecting  ducts,  thus  blocking
he  re-absorption  of  free  water.  This  promotes  water  clear-
nce  without  affecting  sodium  balance.  In  the  Efﬁcacy  of
asopressin  Antagonism  in  Heart  Failure  Outcome  Study  with
olvaptan  (EVEREST)  trial,  tolvaptan  at  a  dose  of  30  mg  once
aily  for  a  minimum  of  60  days  had  no  effect  on  total  mor-
ality  or  HF  hospitalization  when  compared  to  placebo.21,41
Adenosine  antagonists  can  potentially  increase  glomeru-
ar  ﬁltration  and  enhance  the  diuretic  effect  of  diuretic
rugs.  However,  the  Placebo-Controlled  Randomized  Study
f  the  Selective  Adenosine  A1  Receptor  Antagonist  Rolo-
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Heart  Failure  and  Volume  Overload  to  Assess  Treatment
Effect  on  Congestion  and  Renal  Function  (PROTECT)  trial
did  not  report  any  beneﬁcial  effects  on  congestion  or
renal  function  and  was  associated  with  an  increased  risk  of
seizures.21,42
Glucocorticoids  may  promote  diuresis  and  protect  renal
function  in  patients  with  acute  HF.  Liu  et  al.  reported  the
effects  of  prednisolone  in  13  congestive  HF  patients  with
signiﬁcant  volume  overload  and  diuretic  resistance  who
had  failed  to  respond  to  a  conventional  sequential  nephron
blockade  treatment  strategy.  They  reported  an  improve-
ment  in  diuresis,  clinical  status  and  renal  function.43 The
same  author  later  reviewed  the  available  evidence  and  con-
cluded  that  the  short-term  use  of  glucocorticoids,  when
added  to  maximum  conventional  therapy,  can  potentiate
renal  responsiveness  to  diuretic  therapy  in  patients  with
HF.44 However,  larger  randomized  double-blind  placebo-
controlled  studies  are  warranted  to  demonstrate  their  safety
and  efﬁcacy  in  such  patients.  The  proposed  mechanism
of  action  of  glucocorticoids  includes  increased  expression
of  natriuretic  peptide  receptor-A  in  the  kidney  and  the
hypothalamus,  which  appear  to  be  reduced  in  patients  with
HF,  also  increasing  renal  blood  ﬂow  through  dilatation  of  the
renal  vasculature  via  increased  renal  prostaglandin,  nitric
oxide  and  dopamine  production.21,43,44
Levosimendan  was  studied  in  patients  presenting  with
acute  HF  in  the  Randomized  Multicenter  Evaluation  of
Intravenous  Levosimendan  Efﬁcacy  (REVIVE)  studies.  These
showed  that  levosimendan  improved  renal  function  and
diuretic  response  in  such  patients.  However,  there  was  also
an  increased  risk  of  arrhythmia  and  hypotension.21
Ularitide,  a  human  endogenous  natriuretic  peptide
expressed  in  the  kidney,  which  induces  natriuresis  and  diure-
sis  by  binding  to  a  speciﬁc  natriuretic  peptide  receptor,  was
investigated  in  patients  with  acute  HF  in  the  Efﬁcacy  and
Safety  of  Ularitide  for  the  Treatment  of  Acute  Decompen-
sated  Heart  Failure  (TRUE-AHF)  trial.  Packer  et  al.  reported
favorable  physiological  effects  (greater  reductions  in  sys-
tolic  blood  pressure  and  in  levels  of  N-terminal  pro--BNP
[NT-proBNP]  than  the  placebo  group,  without  affecting
cardiac  troponin  levels).  However,  short-term  treatment
neither  affected  the  initial  48-hour  clinical  course  nor
reduced  long-term  cardiovascular  mortality.21,45
In  the  Efﬁcacy  and  Safety  of  Relaxin  for  the  Treatment  of
Acute  Heart  Failure  (RELAX-AHF)  trial,  serelaxin,  a  human
recombinant  form  of  the  vasodilator  relaxin,  showed  no  sig-
niﬁcant  effect  on  diuretic  response,  but  did  have  beneﬁcial
effects  in  preventing  organ  damage  in  patients  with  acute
HF  who  were  diuretic-resistant.21,46 The  Efﬁcacy,  Safety  and
Tolerability  of  Serelaxin  When  Added  to  Standard  Therapy
in  AHF  (RELAX-AHF-2)  trial  was  designed  to  conﬁrm  sere-
laxin’s  effect  on  these  clinical  outcomes  but  it  did  not  meet
either  of  its  primary  endpoints.  There  was  no  difference  in
cardiovascular  mortality  at  180  days  and  the  trend  for  reduc-
ing  worsening  HF  through  day  ﬁve  with  serelaxin  was  not
statistically  signiﬁcant.47
There  are  several  other  agents  under  investigation,  which
could  play  a  role  in  aiding  decongestion  of  patients  pre-
senting  with  acute  HF,  such  as  omecamtiv  mecarbil  and
TRV027.21
Omecamtiv  mecarbil  is  a  selective  cardiac  myosin  activa-





nd  in  patients  with  chronic  HF.  Its  effects  on  patients  with
cute  HF  were  evaluated  in  the  Acute  Treatment  with  Ome-
amtiv  Mecarbil  to  Increase  Contractility  in  Acute  Heart
ailure  (ATOMIC-HF)  trial.  This  study  showed  that  omecam-
iv  mecarbil  may  improve  dyspnea  scores  when  higher  doses
ere  used  in  comparison  to  placebo;  however,  it  did  not
igniﬁcantly  improve  overall  dyspnea  scores  --  the  primary
ndpoint  of  the  study.48
TRV027  is  a  novel  ligand  of  the  angiotensin  II  type
 receptor,  selectively  antagonizing  the  negative  effects
f  angiotensin  II,  while  preserving  the  potential  pro-
ontractility  effects  of  angiotensin  II  type  1  receptor
timulation.  Its  safety  and  efﬁcacy  were  assessed  in  the
iased  ligand  of  the  angiotensin  II  type  1  receptor  in  patients
ith  acute  heart  failure  (BLAST-AHF)  trial  and,  although  well
olerated,  TRV027  did  not  improve  clinical  status  through
0-day  follow-up  compared  to  placebo.49
Further  studies  are  needed  to  evaluate  the  safety  and
fﬁcacy  of  these  drug  candidates  in  a  larger  group  of
atients  with  acute  HF.
ltraﬁltration
F  is  very  effective  at  removing  plasma  ﬂuid  from  blood
cross  a  semipermeable  membrane  that  allows  small
olecules  to  pass  through  along  its  pressure  gradient  to  the
ltraﬁltrate  ﬂuid.21
Small  studies  suggest  that  UF  improves  pulmonary  and
eripheral  edema,  lung  function  and  hemodynamics  without
dverse  effects  on  renal  function.  The  ﬂuid  removal  rate  is
eevaluated  using  clinical  assessment  and  serial  hematocrit
easurements  to  ensure  appropriate  vascular  compartment
eﬁll.21
The  recent  development  of  veno-venous  peripheral  UF
as  positioned  this  technique  as  a  potential  alternative  to
oop  diuretics  in  acute  HF.21
The  Relief  for  Acutely  Fluid-Overloaded  Patients  With
ecompensated  Congestive  Heart  Failure  (RAPID-CHF)  trial,
 multicenter  randomized  controlled  trial  involving  forty
atients,  found  that  UF  was  feasible,  well-tolerated,  and
esulted  in  signiﬁcant  weight  loss  and  ﬂuid  removal.50
Favorable  outcomes  were  also  reported  in  the  Ultra-
ltration  versus  Intravenous  Diuretics  for  Patients  Hospi-
alized  for  Acute  Decompensated  Congestive  Heart  Failure
UNLOAD)  trial.  This  prospective,  randomized,  multicenter
rial  involving  200  patients,  found  that  UF  safely  produces
reater  weight  and  ﬂuid  loss  than  intravenous  diuretics,
educes  90-day  resource  utilization  for  HF  and  is  an  effective
lternative  therapy.51
In  the  Ultraﬁltration  vs.  Diuretics  in  Decompensated  HF
ULTRADISCO)  study,  a  prospective,  randomized,  open-label,
ingle-center  study  which  included  30  patients,  the  use  of
F  was  associated  with  greater  hemodynamic  stability  and
ith  a  greater  reduction  in  plasma  levels  of  NT-proBNP  and
ldosterone  compared  to  diuretic  infusion.52
In  the  Continuous  Ultraﬁltration  for  Congestive  Heart
ailure  (CUORE)  trial,  UF  as  a  ﬁrst-line  treatment  in  patients
ith  severe  congestive  HF  was  associated  with  prolonged
linical  stabilization  and  greater  freedom  from  rehospital-

























































The  Cardiorenal  Rescue  Study  in  Acute  Decompensated
eart  Failure  (CARRESS-HF),  however,  found  a  stepped
harmacologic-therapy  algorithm  to  be  superior  to  UF  for
he  preservation  of  renal  function  at  96  hours,  with  a  simi-
ar  amount  of  weight  loss  seen  with  the  two  approaches  and
 higher  rate  of  adverse  events  observed  with  UF.54
Results  of  the  Reverse  Worsening  Renal  Function  in
ecompensated  Heart  Failure  (REWORD-HF)  study  (which
nded  in  April  2017)  are  still  pending  and  will  help  deter-
ine  whether  ﬂuid  removal  by  UF  is  superior  to  different
harmacological  approaches  in  acutely  relieving  congestion
nd  preventing  further  deterioration  in  renal  function  and
hether  it  results  in  longer  admission-free  survival  90  days
fter  enrolment  in  patients  with  decompensated  HF  and  car-
iorenal  syndrome.
Seven  randomized  controlled  trials,  including  several  of
hose  mentioned  above,  were  submitted  for  a  meta-analysis.
F  was  found  to  be  an  effective  and  safe  therapeu-
ic  strategy,  resulting  in  greater  weight  loss  and  ﬂuid
emoval  without  affecting  renal  function,  mortality  or
ehospitalization.55
The  2016  European  Society  of  Cardiology  guidelines  state
hat  there  is  no  evidence  favoring  UF  over  loop  diuretics
s  ﬁrst-line  therapy  in  patients  with  acute  HF.  The  former
hould  thus  be  conﬁned  to  patients  who  fail  to  respond  to
iuretic-based  strategies.
onclusion
iuretic  resistance  has  emerged  as  an  independent  factor
ehind  worse  HF  patient  outcomes,  namely  in-hospital  wors-
ning,  early  post-discharge  mortality  and  rehospitalizations.
hile  several  mechanisms  help  to  explain  their  reduced
esponse  to  diuretics,  the  deﬁnition  of  the  problem  itself
emains  elusive.  More  recent  evidence  is  leaning  towards
he  coupling  of  parameters  such  as  weight  loss  and  urine
utput  to  diuretic  dose,  but  several  challenges  remain.  Non-
harmacological  measures  and  a  few  medical  options,  such
s  continuous  infusion  of  diuretics  and  sequential  nephron
lockade,  may  be  used  to  overcome  diuretic  resistance.  Nev-
rtheless,  disease  progression  may  warrant  more  invasive
ethods  for  ﬂuid  removal.  Therapy  must  be  tailored  on  a
ase-by-case  basis.
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